loperamide has been researched along with hki 272 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barcenas, CH; Bose, R; Brufsky, A; Chan, A; Cheong, KA; Chien, AJ; DiPrimeo, D; Egle, D; Foruzan, N; García-Sáenz, JA; Hurvitz, SA; Marx, G; McCulloch, L; Pistilli, B; Rugo, HS; Ruiz-Borrego, M; Schnappauf, B; Semsek, D; Singer, CF; Thirlwell, M; Trudeau, M; Wassermann, J | 1 |
| Chien, AJ; Jacob, S; Johnson, M; Melisko, M; Quintal, L; Roque, B; Rugo, HS | 1 |
1 trial(s) available for loperamide and hki 272
| Article | Year |
|---|---|
Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Female; Humans; Loperamide; Quinolines; Receptor, ErbB-2 | 2023 |
1 other study(ies) available for loperamide and hki 272
| Article | Year |
|---|---|
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Budesonide; Colestipol; Diarrhea; Female; Humans; Incidence; Loperamide; Quality of Life; Receptor, ErbB-2 | 2023 |